TherapeuticsMD Stock Price, News & Analysis (NASDAQ:TXMD)

$3.83
+0.12 (+3.23 %)
(As of 09/24/2019 06:00 AM ET)
Today's Range
$3.65
Now: $3.83
$3.85
50-Day Range
$1.9150
MA: $2.97
$3.84
52-Week Range
$1.82
Now: $3.83
$6.90
Volume1.96 million shs
Average Volume3.20 million shs
Market Capitalization$923.88 million
P/E RatioN/A
Dividend YieldN/A
Beta1.7
TherapeuticsMD, Inc operates as a women's health care product company in the United States. The company's hormone therapy drug candidate is the TX-002HR, a natural progesterone formulation for the treatment of secondary amenorrhea without the potentially allergenic component of peanut oil. Its preclinical projects include the development of TX-005HR, a topical progesterone cream; TX-006HR, an estradiol and progesterone topical cream to penetrate human skin; and TX-00THR and TX-0008HR, which are transdermal patch forms. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:TXMD
Previous SymbolNYSEMKT:TXMD
CUSIPN/A
Phone561-961-1900

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$16.10 million
Book Value$0.41 per share

Profitability

Net Income$-132,620,000.00
Net Margins-913.07%

Miscellaneous

Employees241
Market Cap$923.88 million
Next Earnings Date11/6/2019 (Estimated)
OptionableOptionable

Receive TXMD News and Ratings via Email

Sign-up to receive the latest news and ratings for TXMD and its competitors with MarketBeat's FREE daily newsletter.


TherapeuticsMD (NASDAQ:TXMD) Frequently Asked Questions

What is TherapeuticsMD's stock symbol?

TherapeuticsMD trades on the NASDAQ under the ticker symbol "TXMD."

How were TherapeuticsMD's earnings last quarter?

TherapeuticsMD Inc (NASDAQ:TXMD) released its earnings results on Tuesday, August, 6th. The company reported ($0.19) EPS for the quarter, missing the Zacks' consensus estimate of ($0.18) by $0.01. The firm earned $6.08 million during the quarter, compared to analysts' expectations of $5.12 million. TherapeuticsMD had a negative net margin of 913.07% and a negative return on equity of 212.57%. The company's revenue for the quarter was up 60.0% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.15) EPS. View TherapeuticsMD's Earnings History.

When is TherapeuticsMD's next earnings date?

TherapeuticsMD is scheduled to release their next quarterly earnings announcement on Wednesday, November 6th 2019. View Earnings Estimates for TherapeuticsMD.

What price target have analysts set for TXMD?

6 brokers have issued 12 month price targets for TherapeuticsMD's stock. Their predictions range from $3.00 to $13.00. On average, they anticipate TherapeuticsMD's stock price to reach $8.8333 in the next twelve months. This suggests a possible upside of 130.6% from the stock's current price. View Analyst Price Targets for TherapeuticsMD.

What is the consensus analysts' recommendation for TherapeuticsMD?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for TherapeuticsMD in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for TherapeuticsMD.

What are Wall Street analysts saying about TherapeuticsMD stock?

Here are some recent quotes from research analysts about TherapeuticsMD stock:
  • 1. According to Zacks Investment Research, "TherapeuticsMD, Inc. is a specialty pharmaceutical company focused on creating branded prescription, generic prescription and over-the-counter products targeted exclusively for women. It is developing three advanced hormone replacement products designed to alleviate the symptoms of and reduce the health risks resulting from menopause-related hormone deficiencies. TherapeuticsMD, Inc. is based in Boca Raton, Florida. " (5/14/2019)
  • 2. Cantor Fitzgerald analysts commented, "We reiterate our OW rating. The execution behind the launches of Annovera is underappreciated, in our view, and we think peak sales could exceed modest expectations for three drugs that target large unmet needs. Valuation Summary We use a blend of EV/EBITDA and DCF analysis to arrive at our 12-month PT of $27. The Disclosure Section may be found on pages 3 – 4.Valuation We use a blend of EV/EBITDA and DCF analysis to arrive at our 12-month PT of $27." (1/21/2019)

Has TherapeuticsMD been receiving favorable news coverage?

Headlines about TXMD stock have been trending somewhat negative recently, InfoTrie reports. The research firm identifies positive and negative press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. TherapeuticsMD earned a media sentiment score of -1.3 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View News Stories for TherapeuticsMD.

Who are some of TherapeuticsMD's key competitors?

What other stocks do shareholders of TherapeuticsMD own?

Based on aggregate information from My MarketBeat watchlists, some companies that other TherapeuticsMD investors own include Opko Health (OPK), Verastem (VSTM), Teva Pharmaceutical Industries (TEVA), CannTrust (CNTTF), Cleveland-Cliffs (CLF), NVIDIA (NVDA), bluebird bio (BLUE), Horizon Therapeutics (HZNP), Synergy Pharmaceuticals (SGYP) and Micron Technology (MU).

Who are TherapeuticsMD's key executives?

TherapeuticsMD's management team includes the folowing people:
  • Mr. Robert G. Finizio, Co-Founder, CEO & Director (Age 48)
  • Mr. John C. K. Milligan IV, Pres, Sec. & Director (Age 57)
  • Dr. Brian A. Bernick, Co-Founder, Chief Clinical Officer & Director (Age 51)
  • Mr. Daniel Alan Cartwright, CFO & Treasurer (Age 61)
  • Mr. Mitchell L. Krassan, Exec. VP & Chief Strategy Officer (Age 53)

Who are TherapeuticsMD's major shareholders?

TherapeuticsMD's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Price T Rowe Associates Inc. MD (9.11%), Bank of New York Mellon Corp (8.77%), BlackRock Inc. (6.63%), Vanguard Group Inc. (6.04%), Bamco Inc. NY (1.38%) and AXA (1.33%). Company insiders that own TherapeuticsMD stock include Angus C Russell, Brian Bernick, Daniel A Cartwright, Jane F Barlow, John CK Iv Milligan, Jules A Musing, Robert G Finizio and Tommy G Thompson. View Institutional Ownership Trends for TherapeuticsMD.

Which institutional investors are selling TherapeuticsMD stock?

TXMD stock was sold by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp, Morgan Stanley, Price T Rowe Associates Inc. MD, BNP Paribas Arbitrage SA, TD Asset Management Inc., Commonwealth Equity Services LLC, Wells Fargo & Company MN and Cubist Systematic Strategies LLC. Company insiders that have sold TherapeuticsMD company stock in the last year include Brian Bernick, Daniel A Cartwright, John CK Iv Milligan, Jules A Musing and Robert G Finizio. View Insider Buying and Selling for TherapeuticsMD.

Which institutional investors are buying TherapeuticsMD stock?

TXMD stock was bought by a variety of institutional investors in the last quarter, including SG Americas Securities LLC, C WorldWide Group Holding A S, Invesco Ltd., Bamco Inc. NY, Nuveen Asset Management LLC, Vanguard Group Inc., Carlson Capital L P and BlackRock Inc.. Company insiders that have bought TherapeuticsMD stock in the last two years include Angus C Russell, Brian Bernick, Jane F Barlow, John CK Iv Milligan, Robert G Finizio and Tommy G Thompson. View Insider Buying and Selling for TherapeuticsMD.

How do I buy shares of TherapeuticsMD?

Shares of TXMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is TherapeuticsMD's stock price today?

One share of TXMD stock can currently be purchased for approximately $3.83.

How big of a company is TherapeuticsMD?

TherapeuticsMD has a market capitalization of $923.88 million and generates $16.10 million in revenue each year. The company earns $-132,620,000.00 in net income (profit) each year or ($0.59) on an earnings per share basis. TherapeuticsMD employs 241 workers across the globe.View Additional Information About TherapeuticsMD.

What is TherapeuticsMD's official website?

The official website for TherapeuticsMD is http://www.therapeuticsmd.com/.

How can I contact TherapeuticsMD?

TherapeuticsMD's mailing address is 6800 BROKEN SOUND PARKWAY NW, BOCA RATON FL, 33487. The company can be reached via phone at 561-961-1900 or via email at [email protected]


MarketBeat Community Rating for TherapeuticsMD (NASDAQ TXMD)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  310 (Vote Outperform)
Underperform Votes:  263 (Vote Underperform)
Total Votes:  573
MarketBeat's community ratings are surveys of what our community members think about TherapeuticsMD and other stocks. Vote "Outperform" if you believe TXMD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TXMD will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 9/24/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel